Liquidia Technologies has added an additional investor, PPD, Inc., to its Series C financing
Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.